UW to test using MDMA in treatment of severe PTSD
The Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the treatment of severe post-traumatic stress disorder (PTSD).
Review of multiple studies shows early hormone use not associated with cognitive problems in healthy women
Hormone therapy is not associated with cognitive harm for women if therapy begins around the age of menopause in healthy women, according to University of Wisconsin-Madison research presented this week at the 2018 Alzheimer’s Association International Conference (AAIC) in Chicago.
UW–Madison and VA study veterans and Alzheimer’s disease
More than five million Americans are living with Alzheimer’s disease and experts expect that number to triple by 2050. And veterans face a higher risk than the general population.
Study identifies patients who benefit most from dinutuximab-based immunotherapy
Using data from a randomized phase III clinical trial of neuroblastoma patients (treated with or without immunotherapy) performed by the Children’s Oncology Group, researchers from the University of Wisconsin School of Medicine and Public Health found that a subset of patients, identified by the presence of a certain set of genes, were more likely to benefit from the immunotherapy than those patients that did not have that set of genes.
UW Carbone Cancer Center researchers win two national prostate cancer awards
UW Carbone Cancer Center researchers won two of the six national Challenge Awards announced this week by the Prostate Cancer Foundation and the Movember Foundation.
Aly Wolff’s dream lives on with new clinical trial
Aly Wolff died of neuroendocrine cancer on April 22, 2013, however her courageous battle continues. Today, three years later, a new clinical trial at the University of Wisconsin Carbone Cancer Center has been approved and holds great promise in offering a new line of treatment for those with neuroendocrine tumors.